Kaplan Fox is Investigating Potential Securities Law Violations Against Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY - May 15, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you are an Iovance investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.
On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024.
Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
[email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
[email protected]
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/iovance-biotherapeutics-inc/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
36 minutes ago
- USA Today
US stock futures little changed as investors await US-China trade talk news
US stock futures little changed as investors await US-China trade talk news Show Caption Hide Caption How fentanyl reaches the US and the role of Trump's China tariffs US President Donald Trump has imposed new tariffs on Chinese goods, citing Beijing's failure to stop the export of chemicals used to produce fentanyl. unbranded - Newsworthy U.S. stock futures are little changed as investors continue to wait for news from U.S.-China trade talks in London. Talks are expected to continue for a second day. Earlier, Kevin Hassett, director of the National Economic Council, said he expected an agreement to emerge that would loosen controls on U.S. exports of semiconductors in exchange for China's releasing of more rare earths. The London talks follow a phone call between President Donald Trump and Chinese leader Xi Jinping, the first between the two since Trump took office and after Trump accused China of violating terms of a tariff pause agreed upon in Switzerland last month. At 6:45 a.m. ET, futures on the blue-chip Dow dropped -0.06%, while broad S&P 500 futures added 0.06% and tech-laden Nasdaq futures rose 0.09%. Later this week, investors will see May inflation data. The May reports will reflect the first full month of price changes since Trump announced aggressive tariffs on April 2. Since then, many of the highest tariffs have been put on ice but others have gone into effect. Corporate news Cracker Barrel Old Country Store said it plans to sell $275 million in convertible senior notes due in 2030 in a private offering. Limoneira said its fiscal second quarter results were worse than in the year-ago period. Cryptocurrency Paraguay President Santiago Pena's X account had likely been hacked to say that the Latin American country had made Bitcoin legal tender and that it would roll out a $5 million Bitcoin-backed reserve fund. The post was deleted and the government said "the president's official X account has presented irregular activity which suggests possible unauthorized entry." Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning.
Yahoo
37 minutes ago
- Yahoo
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the 'Investors' section of Pharvaris' website under 'Events & Presentations'. The documents will also be made available on the SEC's website at Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting. About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit CONTACT: Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications
Yahoo
37 minutes ago
- Yahoo
US stock futures little changed as investors await US-China trade talk news
U.S. stock futures are little changed as investors continue to wait for news from U.S.-China trade talks in London. Talks are expected to continue for a second day. Earlier, Kevin Hassett, director of the National Economic Council, said he expected an agreement to emerge that would loosen controls on U.S. exports of semiconductors in exchange for China's releasing of more rare earths. The London talks follow a phone call between President Donald Trump and Chinese leader Xi Jinping, the first between the two since Trump took office and after Trump accused China of violating terms of a tariff pause agreed upon in Switzerland last month. At 6:45 a.m. ET, futures on the blue-chip Dow dropped -0.06%, while broad S&P 500 futures added 0.06% and tech-laden Nasdaq futures rose 0.09%. Later this week, investors will see May inflation data. The May reports will reflect the first full month of price changes since Trump announced aggressive tariffs on April 2. Since then, many of the highest tariffs have been put on ice but others have gone into effect. Cracker Barrel Old Country Store said it plans to sell $275 million in convertible senior notes due in 2030 in a private offering. Limoneira said its fiscal second quarter results were worse than in the year-ago period. Paraguay President Santiago Pena's X account had likely been hacked to say that the Latin American country had made Bitcoin legal tender and that it would roll out a $5 million Bitcoin-backed reserve fund. The post was deleted and the government said "the president's official X account has presented irregular activity which suggests possible unauthorized entry." Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning. This article originally appeared on USA TODAY: US stock futures little changed amid US-China trade talks
